Antitumor effect of novel small chemical inhibitors of Snail-p53 binding in K-Ras-mutated cancer cells

S. H. Lee; G. N. Shen; Y. S. Jung; S. J. Lee; J. Y. Chung; H. S. Kim; Y. Xu; Y. Choi; J. W. Lee; N. C. Ha; G. Y. Song; B. J. Park

doi:10.1038/onc.2010.208

Antitumor effect of novel small chemical inhibitors of Snail-p53 binding in K-Ras-mutated cancer cells

S. H. Lee, G. N. Shen, Y. S. Jung, S. J. Lee, J. Y. Chung, H. S. Kim, Y. Xu, Y. Choi, J. W. Lee, N. C. Ha, G. Y. Song, B. J. Park

Research output: Contribution to journal › Article › peer-review

37 Citations (Scopus)

Abstract

p53 is frequently mutated by genetic alternation or suppressed by various kinds of cellular signaling pathways in human cancers. Recently, we have revealed that p53 is suppressed and eliminated from cells by direct binding with oncogenic K-Ras-induced Snail. On the basis of the fact, we generated specific inhibitors against p53-Snail binding (GN25 and GN29). These chemicals can induce p53 expression and functions in K-Ras-mutated cells. However, it does not show cytotoxic effect on normal cells or K-Ras-wild-type cells. Moreover, GN25 can selectively activate wild-type p53 in p53 WT/MT cancer cells. But single allelic mt p53 containing cell line, Panc-1, does not respond to our chemical. In vivo xenograft test also supports the antitumor effect of GN25 in K-Ras-mutated cell lines. These results suggest that our compounds are strong candidate for anticancer drug against K-Ras-initiated human cancers including pancreatic and lung cancers.

Original language	English
Pages (from-to)	4576-4587
Number of pages	12
Journal	Oncogene
Volume	29
Issue number	32
DOIs	https://doi.org/10.1038/onc.2010.208
Publication status	Published - 2010 Aug 12

Bibliographical note

Funding Information:
This work was supported by national cancer center of Korea (0920250; BJP), by the Bio-Scientific Research Grant funded by the Pusan National University (PNU-2008-101-20080596000; BJP) and by the Priority Research Center Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2009-0093815; GYS).

Keywords

K-Ras
Snail
anticancer drug
p53
pancreatic cancer

ASJC Scopus subject areas

Molecular Biology
Genetics
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/onc.2010.208

Cite this

@article{0f251f8f748146dabec20a4e024ed167,

title = "Antitumor effect of novel small chemical inhibitors of Snail-p53 binding in K-Ras-mutated cancer cells",

abstract = "p53 is frequently mutated by genetic alternation or suppressed by various kinds of cellular signaling pathways in human cancers. Recently, we have revealed that p53 is suppressed and eliminated from cells by direct binding with oncogenic K-Ras-induced Snail. On the basis of the fact, we generated specific inhibitors against p53-Snail binding (GN25 and GN29). These chemicals can induce p53 expression and functions in K-Ras-mutated cells. However, it does not show cytotoxic effect on normal cells or K-Ras-wild-type cells. Moreover, GN25 can selectively activate wild-type p53 in p53 WT/MT cancer cells. But single allelic mt p53 containing cell line, Panc-1, does not respond to our chemical. In vivo xenograft test also supports the antitumor effect of GN25 in K-Ras-mutated cell lines. These results suggest that our compounds are strong candidate for anticancer drug against K-Ras-initiated human cancers including pancreatic and lung cancers.",

keywords = "K-Ras, Snail, anticancer drug, p53, pancreatic cancer",

author = "Lee, {S. H.} and Shen, {G. N.} and Jung, {Y. S.} and Lee, {S. J.} and Chung, {J. Y.} and Kim, {H. S.} and Y. Xu and Y. Choi and Lee, {J. W.} and Ha, {N. C.} and Song, {G. Y.} and Park, {B. J.}",

note = "Funding Information: This work was supported by national cancer center of Korea (0920250; BJP), by the Bio-Scientific Research Grant funded by the Pusan National University (PNU-2008-101-20080596000; BJP) and by the Priority Research Center Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2009-0093815; GYS).",

year = "2010",

month = aug,

day = "12",

doi = "10.1038/onc.2010.208",

language = "English",

volume = "29",

pages = "4576--4587",

journal = "Oncogene",

issn = "0950-9232",

publisher = "Springer Nature",

number = "32",

}

TY - JOUR

T1 - Antitumor effect of novel small chemical inhibitors of Snail-p53 binding in K-Ras-mutated cancer cells

AU - Lee, S. H.

AU - Shen, G. N.

AU - Jung, Y. S.

AU - Lee, S. J.

AU - Chung, J. Y.

AU - Kim, H. S.

AU - Xu, Y.

AU - Choi, Y.

AU - Lee, J. W.

AU - Ha, N. C.

AU - Song, G. Y.

AU - Park, B. J.

N1 - Funding Information: This work was supported by national cancer center of Korea (0920250; BJP), by the Bio-Scientific Research Grant funded by the Pusan National University (PNU-2008-101-20080596000; BJP) and by the Priority Research Center Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2009-0093815; GYS).

PY - 2010/8/12

Y1 - 2010/8/12

N2 - p53 is frequently mutated by genetic alternation or suppressed by various kinds of cellular signaling pathways in human cancers. Recently, we have revealed that p53 is suppressed and eliminated from cells by direct binding with oncogenic K-Ras-induced Snail. On the basis of the fact, we generated specific inhibitors against p53-Snail binding (GN25 and GN29). These chemicals can induce p53 expression and functions in K-Ras-mutated cells. However, it does not show cytotoxic effect on normal cells or K-Ras-wild-type cells. Moreover, GN25 can selectively activate wild-type p53 in p53 WT/MT cancer cells. But single allelic mt p53 containing cell line, Panc-1, does not respond to our chemical. In vivo xenograft test also supports the antitumor effect of GN25 in K-Ras-mutated cell lines. These results suggest that our compounds are strong candidate for anticancer drug against K-Ras-initiated human cancers including pancreatic and lung cancers.

AB - p53 is frequently mutated by genetic alternation or suppressed by various kinds of cellular signaling pathways in human cancers. Recently, we have revealed that p53 is suppressed and eliminated from cells by direct binding with oncogenic K-Ras-induced Snail. On the basis of the fact, we generated specific inhibitors against p53-Snail binding (GN25 and GN29). These chemicals can induce p53 expression and functions in K-Ras-mutated cells. However, it does not show cytotoxic effect on normal cells or K-Ras-wild-type cells. Moreover, GN25 can selectively activate wild-type p53 in p53 WT/MT cancer cells. But single allelic mt p53 containing cell line, Panc-1, does not respond to our chemical. In vivo xenograft test also supports the antitumor effect of GN25 in K-Ras-mutated cell lines. These results suggest that our compounds are strong candidate for anticancer drug against K-Ras-initiated human cancers including pancreatic and lung cancers.

KW - K-Ras

KW - Snail

KW - anticancer drug

KW - p53

KW - pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=77955659716&partnerID=8YFLogxK

U2 - 10.1038/onc.2010.208

DO - 10.1038/onc.2010.208

M3 - Article

C2 - 20531295

AN - SCOPUS:77955659716

SN - 0950-9232

VL - 29

SP - 4576

EP - 4587

JO - Oncogene

JF - Oncogene

IS - 32

ER -

Antitumor effect of novel small chemical inhibitors of Snail-p53 binding in K-Ras-mutated cancer cells

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this